Current evidence on GnRH agonist pretreatment before frozen embryo transfer and pregnancy outcomes in women with adenomyosis: a systematic review and meta-analysis

In: Research Square · 2026 · doi:10.21203/rs.3.rs-11527100/v1 · W7234933650
Systematic review / meta-analysis preprint OA: green CC0

Abstract

Abstract Adenomyosis is increasingly recognized as an important cause of infertility and reduced success rates in assisted reproductive technology (ART). Women with adenomyosis undergoing frozen embryo transfer (FET) have lower implantation and live birth rates compared to women without the disease. Gonadotropin-releasing hormone agonist (GnRH-a) pretreatment before FET has been proposed to improve reproductive outcomes by suppressing adenomyotic activity and enhancing endometrial receptivity; however, published studies have reported conflicting findings. The objective of this review was to evaluate the current evidence regarding the effectiveness of GnRH-a pretreatment before FET in women with adenomyosis. A systematic search of MEDLINE, EMBASE, Cochrane Library, Web of Science, and SCOPUS was performed up to November 9, 2024. Ten eligible studies, including randomized controlled trials and retrospective cohort studies, were identified. Outcomes included live birth, clinical pregnancy, biochemical pregnancy, and miscarriage rates. Although none of the pooled analyses reached statistical significance, GnRH-a pretreatment showed a consistent trend toward improved live birth and clinical pregnancy outcomes. The odds ratio for live birth was 1.47 per cycle and 1.23 per patient, favouring pretreatment. Clinical pregnancy rates also tended to improve, while biochemical pregnancy and miscarriage rates remained similar between groups. Current evidence suggests that GnRH-a pretreatment before FET may improve reproductive outcomes in women with adenomyosis, particularly live birth rates, although the quality of evidence remains limited by heterogeneity, retrospective study design, and inconsistent diagnostic criteria. These findings support the potential role of GnRH-a pretreatment in selected patients while highlighting the need for large, well-designed randomized controlled trials to establish clear clinical recommendations.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Source provenance

europepmc
last seen: 2026-11-19T08:37:55.746041+00:00
openalex
last seen: 2026-11-19T06:04:33.792782+00:00
License: CC0 · commercial use OK